Ann: Appendix 4E and Full Year Statutory Accounts, page-2

The submission of the CTA is a significant milestone for the Company encapsulating an extensive effort by the
Company in establishing an agreed clinical and regulatory pathway with the European Medicines Agency and in
preparing the comprehensive documentation package required by the regulators for trial approval. Company also
advised that is was evaluating its clinical plans for ATL1102 in DMD and expected to provide a program update in
the 3Q’22.

Now this part is a bit scary...Evaluation of clinical plans and it's update. What could that be ???

You already have an application in Germany....what you are going to put that on hold or put the whole trial on hold?

What else could that be..

It's always clear as mud..